pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 (Q34123654)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

5

object named as

Bence Sipos

0 references

Ursula Vehling-Kaiser

11

object named as

Ursula Vehling-Kaiser

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ludwig Fischer von Weikersthal

13

object named as

Ludwig Fischer von Weikersthal

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

object named as

Stephan Kruger

10

0 references

Anna Melissa Schlitter

6

object named as

Anna Melissa Schlitter

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

object named as

Irene Esposito

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Steffen Ormanns

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jens T Siveke

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Volker Heinemann

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael Haas

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Andreas Jung

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rüdiger P Laubender

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cornelia Winkelmann

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael R Clemens

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Thomas C Gauler

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Angela Märten

16

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael Geissler

17

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Tim F Greten

18

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Thomas Kirchner

19

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Stefan Boeck

20

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

28 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

624

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Therapeutic advances in pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Overexpression of p53 protein in human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

EGF receptor is required for KRAS-induced pancreatic tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Systemic treatment of advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

5 July 2018

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-624

21 January 2018

Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-624

21 January 2018

Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-624

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-624

21 January 2018

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-624

21 January 2018

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4152581

28 October 2018

Identifiers

10.1186/1471-2407-14-624

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34123654&oldid=2196280476"